

Development of evidence-based clinical guidelines for hepatocellular carcinoma in Japan

Hepatology Research

38, 37-51

DOI: [10.1111/j.1872-034x.2007.00216.x](https://doi.org/10.1111/j.1872-034x.2007.00216.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium.. American Journal of Roentgenology, 1999, 172, 969-976.	2.2	329
3	Preventative hepatology: minimising symptoms and optimising care. Liver International, 2008, 28, 922-934.	3.9	28
4	Hepatocellular Carcinoma 2009 and Beyond: from the Surveillance to Molecular Targeted Therapy. Oncology, 2008, 75, 1-12.	1.9	108
5	Hepatocellular carcinoma for the non-specialist. BMJ: British Medical Journal, 2009, 339, b5039-b5039.	2.3	21
7	Proton beam therapy for hepatocellular carcinoma. Cancer, 2009, 115, 5499-5506.	4.1	122
8	Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. Journal of Gastroenterology, 2009, 44, 119-121.	5.1	124
9	Image-guided percutaneous ablation therapies for hepatocellular carcinoma. Journal of Gastroenterology, 2009, 44, 122-131.	5.1	28
10	Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatology International, 2009, 3, 544-550.	4.2	69
11	Hepatocellular carcinoma in the Asia pacific region. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 346-353.	2.8	407
12	Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 955-961.	2.8	65
13	Prevention of hepatocellular carcinoma complicating chronic hepatitis C. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 531-536.	2.8	40
14	Screening and diagnosis of hepatocellular carcinoma. Liver International, 2009, 29, 143-147.	3.9	42
15	Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma. Liver International, 2010, 30, 1027-1032.	3.9	18
16	Liver Resection Improves the Survival of Patients with Multiple Hepatocellular Carcinomas. Annals of Surgical Oncology, 2009, 16, 848-855.	1.5	105
17	Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method – Analysis of 2010 Taiwanese patients. European Journal of Cancer, 2009, 45, 1630-1639.	2.8	72
18	Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. Journal of Hepatology, 2009, 51, 315-321.	3.7	84
19	Assessment of liver function for safe hepatic resection. Hepatology Research, 2009, 39, 107-116.	3.4	180
20	Risk factors for postoperative recurrence of non-EB non-EC hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2010, 17, 291-295.	2.6	8

#	ARTICLE	IF	CITATIONS
21	Surgical technique: new advances for expanding indications and increasing safety in liver resection for HCC. Journal of Hepato-Biliary-Pancreatic Sciences, 2010, 17, 389-393.	2.6	29
22	Single HCC between 2 and 5 cm: the grey zone. Journal of Hepato-Biliary-Pancreatic Sciences, 2010, 17, 434-437.	2.6	3
23	Comparison of the outcomes between anatomical resection and limited resection for single hepatocellular carcinomas no larger than 5 cm in diameter: a single-center study. Journal of Hepato-Biliary-Pancreatic Sciences, 2010, 17, 349-358.	2.6	32
24	Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus. Journal of Gastroenterology, 2010, 45, 105-112.	5.1	29
25	AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. Journal of Gastroenterology, 2010, 45, 1272-1282.	5.1	157
26	Selecting treatment for hepatocellular carcinoma based on the results of hepatic resection and local ablation therapy. Journal of Surgical Oncology, 2010, 101, 481-485.	1.7	11
27	Prevention of hepatocellular carcinoma in the Asia-Pacific region: Consensus statements. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 657-663.	2.8	134
28	The 2008 Okuda lecture: Management of hepatocellular carcinoma: From surveillance to molecular targeted therapy. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 439-452.	2.8	98
29	Optimal management of hepatocellular carcinoma: Challenges and opportunities. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1336-1338.	2.8	10
30	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers. Clinical Chemistry, 2010, 56, e1-e48.	3.2	184
31	Real Practice of Hepatocellular Carcinoma in Japan: Conclusions of the Japan Society of Hepatology 2009 Kobe Congress. Oncology, 2010, 78, 180-188.	1.9	46
32	Liver Cancer Working Group Report. Japanese Journal of Clinical Oncology, 2010, 40, i19-i27.	1.3	65
33	Current Approaches to the Treatment of Early Hepatocellular Carcinoma. Oncologist, 2010, 15, 34-41.	3.7	50
34	The Etiology of Hepatocellular Carcinoma and Consequences for Treatment. Oncologist, 2010, 15, 14-22.	3.7	437
35	Management of Hepatocellular Carcinoma: From Prevention to Molecular Targeted Therapy. Oncology, 2010, 78, 1-6.	1.9	17
36	Contrast-Enhanced Ultrasound Techniques for Guiding and Assessing Response to Locoregional Treatments for Hepatocellular Carcinoma. Oncology, 2010, 78, 68-77.	1.9	11
37	Radiofrequency Ablation for Hepatocellular Carcinoma: Updated Review in 2010. Oncology, 2010, 78, 113-124.	1.9	134
38	Chemoembolization for Unresectable Hepatocellular Carcinoma in Japan. Oncology, 2010, 78, 135-141.	1.9	12

#	ARTICLE	IF	CITATIONS
39	Targeted Sonography for Small Hepatocellular Carcinoma Discovered by CT or MRI: Factors Affecting Sonographic Detection. American Journal of Roentgenology, 2010, 194, W396-W400.	2.2	97
40	Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma. Journal of Experimental and Clinical Medicine, 2010, 2, 93-103.	0.2	21
41	Des-Î ³ -Carboxy Prothrombin and Î ¹ -Fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma. Gastroenterology, 2010, 138, 493-502.	1.3	524
42	Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design. Contemporary Clinical Trials, 2010, 31, 55-61.	1.8	46
43	Combination of transarterial chemoembolization and percutaneous local ablation therapy for hepatocellular carcinoma. Hepatology Research, 2010, 40, 105-107.	3.4	1
44	Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatology Research, 2010, 40, 667-685.	3.4	154
45	Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: A randomized control trial. Oncology Reports, 2011, 26, 1547-53.	2.6	41
46	Hepatocellular Carcinoma in 2011 and Beyond: From the Pathogenesis to Molecular Targeted Therapy. Oncology, 2011, 81, 1-10.	1.9	23
47	Hepatocellular Carcinoma: , 2011, , .		4
48	Laparoscopic Liver Resection in the Treatment of Hepatocellular Carcinoma. Clinics in Liver Disease, 2011, 15, 371-384.	2.1	12
49	Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatology Research, 2011, 41, 405-416.	3.4	39
50	Demonstration of quality of care measurement using the Japanese liver cancer registry. Hepatology Research, 2011, 41, 1208-1215.	3.4	17
51	Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. International Journal of Oncology, 2012, 40, 63-70.	3.3	54
52	Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents. Oncology Letters, 2011, 2, 69-73.	1.8	6
53	Percutaneous Sonographically Guided Radio Frequency Ablation of Hepatocellular Carcinoma. Journal of Ultrasound in Medicine, 2011, 30, 607-615.	1.7	37
54	Autoimmune Hepatitis, Cirrhosis, and Hepatocellular Carcinoma (HCC). Digestive Diseases and Sciences, 2011, 56, 276-278.	2.3	20
55	Phenotype-dependent production of des-Î ³ -carboxy prothrombin in hepatocellular carcinoma. Journal of Gastroenterology, 2011, 46, 1219-1229.	5.1	9
56	Hepatocarcinogenesis: imaging-pathologic correlation. Abdominal Imaging, 2011, 36, 232-243.	2.0	45

#	ARTICLE	IF	CITATIONS
57	Chemoprevention against hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2011, 4, 185-197.	0.8	14
58	Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: A long-term cohort study. Hepatology, 2011, 53, 136-147.	7.3	159
59	Surveillance for hepatocellular carcinoma: A standard of care, not a clinical option. Hepatology, 2011, 54, 1898-1900.	7.3	12
60	Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. International Journal of Cancer, 2011, 129, 1923-1931.	5.1	77
61	Intraoperative Ultrasound Score to Predict Recurrent Hepatocellular Carcinoma After Radical Treatments. Ultrasound in Medicine and Biology, 2011, 37, 7-15.	1.5	7
62	A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α -fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Clinical Chemistry and Laboratory Medicine, 2011, 49, 711-718.	2.3	52
63	Surgical Treatment for Hepatocellular Carcinoma. Japanese Journal of Clinical Oncology, 2011, 41, 447-454.	1.3	58
64	Hepatocellular Carcinoma: Current Management and Future Developmentâ€”Improved Outcomes with Surgical Resection. International Journal of Hepatology, 2011, 2011, 1-10.	1.1	53
65	Superselective Transarterial Chemoembolization for Hepatocellular Carcinoma: Recent Progression and Perspective. Oncology, 2011, 81, 105-110.	1.9	7
66	Living Donor Liver Transplantation for Hepatocellular Carcinoma: The Japanese Experience. Oncology, 2011, 81, 111-115.	1.9	17
67	Recent Advances in Radiofrequency Ablation for the Management of Hepatocellular Carcinoma. Hepatitis Monthly, 2012, 12, e5945.	0.2	12
68	Transarterial Chemoembolization for Hepatocellular Carcinoma over Three Decades: Current Progress and Perspective. Japanese Journal of Clinical Oncology, 2012, 42, 247-255.	1.3	39
69	Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma: Fusion Imaging Guidance for Management of Lesions With Poor Conspicuity at Conventional Sonography. American Journal of Roentgenology, 2012, 198, 1438-1444.	2.2	98
70	Frequency of Elevated Hepatocellular Carcinoma (HCC) Biomarkers in Patients With Advanced Hepatitis C. American Journal of Gastroenterology, 2012, 107, 64-74.	0.4	100
71	Perspectives on The Design of Clinical Trials Combining Transarterial Chemoembolization and Molecular Targeted Therapy. Liver Cancer, 2012, 1, 168-176.	7.7	19
72	Preventive effect of caffeine and curcumin on hepato- $\text{A}^{1/2}$ carcinogenesis in diethylnitrosamine-induced rats. International Journal of Oncology, 2012, 40, 1779-88.	3.3	8
73	mTOR as a Potential Target for the Prevention and Treatment of Hepatocellular Carcinoma. Current Cancer Drug Targets, 2012, 12, 1045-1061.	1.6	22
74	Hepatocellular Carcinoma Diagnostics, Treatments and Potential Theragnostics in the Asia-Pacific. Current Pharmacogenomics and Personalized Medicine, 2012, 10, 159-169.	0.2	0

#	ARTICLE	IF	CITATIONS
75	Liver Resection for Hepatocellular Carcinoma ≤3 cm: Results of an Italian Multicenter Study on 588 Patients. <i>Journal of the American College of Surgeons</i> , 2012, 215, 244-254.	0.5	51
76	Planning Ultrasound for Percutaneous Radiofrequency Ablation to Treat Small (≤3 cm) Hepatocellular Carcinomas Detected on Computed Tomography or Magnetic Resonance Imaging: A Multicenter Prospective Study to Assess Factors Affecting Ultrasound Visibility. <i>Journal of Vascular and Interventional Radiology</i> , 2012, 23, 627-634.	0.5	73
77	The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. <i>Liver International</i> , 2012, 32, 1053-1063.	3.9	101
78	Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. <i>Journal of Hepatology</i> , 2012, 56, 886-892.	3.7	191
79	EASL/EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 908-943.	3.7	5,214
80	Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence. <i>Journal of Hepatology</i> , 2012, 57, 330-336.	3.7	17
81	EASL/EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2012, 48, 599-641.	2.8	406
82	Development of hepatocellular carcinomas in patients with absence of tumors on a prior ultrasound examination. <i>European Journal of Radiology</i> , 2012, 81, 1450-1454.	2.6	10
83	Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2012, 10, 107.	1.9	59
84	Surveillance for Hepatocellular Carcinoma. <i>Seminars in Oncology</i> , 2012, 39, 384-398.	2.2	52
85	Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds: Trans-arterial radio-embolisation of HCC. <i>Cancer Treatment Reviews</i> , 2012, 38, 641-649.	7.7	38
86	Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma. <i>Medical Oncology</i> , 2012, 29, 2800-2808.	2.5	52
87	Risk of hypervascularization in small hypovascular hepatic nodules showing hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease. <i>Japanese Journal of Radiology</i> , 2012, 30, 743-751.	2.4	28
88	Improvement and Multicenter Evaluation of the Analytical Performance of an Automated Chemiluminescent Immunoassay for Alpha Fetoprotein. <i>International Journal of Biological Markers</i> , 2012, 27, 39-46.	1.8	7
89	Correlation of liver parenchymal gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid enhancement and liver function in humans with hepatocellular carcinoma. <i>Oncology Letters</i> , 2012, 3, 990-994.	1.8	29
90	Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report. <i>Journal of Medical Case Reports</i> , 2012, 6, 38.	0.8	11
91	Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2012, 47, 421-426.	5.1	34
92	Clinical utility of serum fucosylated hemopexin in Japanese patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2012, 42, 1187-1195.	3.4	17

#	ARTICLE	IF	CITATIONS
93	Predictors for Microinvasion of Small Hepatocellular Carcinoma 2cm. Annals of Surgical Oncology, 2012, 19, 2027-2034.	1.5	123
94	Significance of anatomic resection for early and advanced hepatocellular carcinoma. Langenbeck's Archives of Surgery, 2012, 397, 85-92.	1.9	15
95	Could radiofrequency ablation replace liver resection for small hepatocellular carcinoma in patients with compensated cirrhosis? A 5-year follow-up. Langenbeck's Archives of Surgery, 2013, 398, 55-62.	1.9	18
96	Current chemotherapies for advanced hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2013, 6, 89-93.	0.8	2
97	Cost-effectiveness of liver cancer screening. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 961-972.	2.4	39
98	New Paradigms in Post-hepatectomy Liver Failure. Journal of Gastrointestinal Surgery, 2013, 17, 593-605.	1.7	74
99	A new approach for elimination of gastric cancer deaths in Japan. International Journal of Cancer, 2013, 132, 1272-1276.	5.1	116
100	Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: A propensity score analysis. Journal of Hepatology, 2013, 58, 427-433.	3.7	124
101	Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. Digestive and Liver Disease, 2013, 45, 712-723.	0.9	155
102	Characteristics of elderly hepatitis C virus-associated hepatocellular carcinoma patients. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 357-364.	2.8	11
103	Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3cm. Liver International, 2013, 33, 762-770.	3.9	52
104	Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Recent Progression and Perspective. Oncology, 2013, 84, 28-33.	1.9	12
105	Imaging-Based Diagnostic Systems for Hepatocellular Carcinoma. American Journal of Roentgenology, 2013, 201, 41-55.	2.2	61
106	Biomarkers: Evaluation of Screening for and Early Diagnosis of Hepatocellular Carcinoma in Japan and China. Liver Cancer, 2013, 2, 31-39.	7.7	90
107	Hypovascular Nodules in Patients with Chronic Liver Disease: Risk Factors for Development of Hypervascular Hepatocellular Carcinoma. Radiology, 2013, 266, 480-490.	7.3	126
108	Glycyrrhizin Represses Total Parenteral Nutrition-Associated Acute Liver Injury in Rats by Suppressing Endoplasmic Reticulum Stress. International Journal of Molecular Sciences, 2013, 14, 12563-12580.	4.1	23
109	A Case of Inflammatory Pseudotumor of the Liver Mimicking Hepatocellular Carcinoma on EOB-MRI and PET. Case Reports in Medicine, 2013, 2013, 1-7.	0.7	12
110	Establishing a Quality Measurement System for Cancer Care in Japan. Japanese Journal of Clinical Oncology, 2013, 43, 225-232.	1.3	20

#	ARTICLE	IF	CITATIONS
111	Hepatic resection for hepatocellular carcinoma based on tumor hemodynamics. Hepatology Research, 2013, 43, 155-164.	3.4	20
112	Comparison between hepatic resection and radiofrequency ablation as first-line treatment for solitary small-sized hepatocellular carcinoma of 3 cm or less. Hepatology Research, 2013, 43, 853-864.	3.4	62
113	Screening for and surveillance of high-risk patients with HBV-related chronic liver disease: Promoting the early detection of hepatocellular carcinoma in China. BioScience Trends, 2013, , .	3.4	35
114	Standardizing management of hepatocellular carcinoma in China: Devising evidence-based clinical practice guidelines. BioScience Trends, 2013, , .	3.4	5
115	Early increase in α -fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. European Journal of Gastroenterology and Hepatology, 2013, 25, 683-689.	1.6	73
116	Pretreatment Evaluation with Contrast-Enhanced Ultrasonography for Percutaneous Radiofrequency Ablation of Hepatocellular Carcinomas with Poor Conspicuity on Conventional Ultrasonography. Korean Journal of Radiology, 2013, 14, 754.	3.4	26
117	Hepatocellular Carcinoma in Child-Pugh C Cirrhosis: Prognostic Factors and Survival Benefit of Nontransplant Treatments. Digestive Diseases, 2013, 31, 490-498.	1.9	25
119	Safety of hepatectomy for elderly patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 15028.	3.3	44
120	Role of surgical resection for hepatocellular carcinoma based on Japanese clinical guidelines for hepatocellular carcinoma. World Journal of Hepatology, 2014, 7, 261.	2.0	14
121	Systematic evidence-based clinical practice guidelines are ushering in a new stage of standardized management of hepatocellular carcinoma in Japan. Drug Discoveries and Therapeutics, 2014, 8, 64-70.	1.5	10
122	Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. Liver International, 2014, 34, 174-183.	3.9	68
123	Reply. Hepatology, 2014, 60, 764-764.	7.3	1
124	High ubiquitous mitochondrial creatine kinase expression in hepatocellular carcinoma denotes a poor prognosis with highly malignant potential. International Journal of Cancer, 2014, 134, 2189-2198.	5.1	27
125	Increased serum mitochondrial creatine kinase activity as a risk for hepatocarcinogenesis in chronic hepatitis C patients. International Journal of Cancer, 2014, 135, 871-879.	5.1	6
126	Consensus report from the 6th International forum for liver MRI using gadoxetic acid. Journal of Magnetic Resonance Imaging, 2014, 40, 516-529.	3.4	40
127	Cause-specific mortality associated with aging in patients with hepatocellular carcinoma undergoing percutaneous radiofrequency ablation. European Journal of Gastroenterology and Hepatology, 2014, 26, 1039-1046.	1.6	10
128	Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World Journal of Hepatology, 2014, 7, 139.	2.0	72
129	Perspectives on a combined test of multi serum biomarkers in China: Towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Drug Discoveries and Therapeutics, 2014, 8, 102-109.	1.5	27

#	ARTICLE	IF	CITATIONS
130	Null anticarcinogenic effect of silymarin on diethylnitrosamine-induced hepatocarcinogenesis in rats. <i>Experimental and Therapeutic Medicine</i> , 2014, 7, 31-38.	1.8	19
131	Roadmap to eliminate gastric cancer with <i>Helicobacter pylori</i> eradication and consecutive surveillance in Japan. <i>Journal of Gastroenterology</i> , 2014, 49, 1-8.	5.1	110
133	High-sensitivity <i>Lens culinaris</i> agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2014, 49, 555-563.	5.1	57
134	CD34 ⁺ cell therapy is safe and effective in slowing the decline of hepatic reserve function in patients with decompensated liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1830-1838.	2.8	21
135	Dynamic analysis of a needle insertion for soft materials: Arbitrary Lagrangian-Eulerian-based three-dimensional finite element analysis. <i>Computers in Biology and Medicine</i> , 2014, 53, 42-47.	7.0	37
136	Tips for anatomical hepatectomy for hepatocellular carcinoma by the G ₁ lissonean pedicle approach (with videos). <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2014, 21, E53-6.	2.6	41
137	Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5. <i>Medical Oncology</i> , 2014, 31, 95.	2.5	15
139	Number of Nodules, Child-Pugh Status, Margin Positivity, and Microvascular Invasion, but not Tumor Size, are Prognostic Factors of Survival after Liver Resection for Multifocal Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 1477-1485.	1.7	57
140	Strategies for eliminating death from gastric cancer in Japan. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2014, 90, 251-258.	3.8	42
141	Section 4. Further Expanding the Criteria for HCC in Living Donor Liver Transplantation. <i>Transplantation</i> , 2014, 97, S17-S20.	1.0	9
142	Nationwide Study of 4741 Patients With Non-B Non-C Hepatocellular Carcinoma With Special Reference to the Therapeutic Impact. <i>Annals of Surgery</i> , 2014, 259, 336-345.	4.2	62
143	Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. <i>Liver International</i> , 2015, 35, 2155-2166.	3.9	813
144	Surgical results for recurrent hepatocellular carcinoma after curative hepatectomy: Repeat hepatectomy versus salvage living donor liver transplantation. <i>Liver Transplantation</i> , 2015, 21, 961-968.	2.4	36
145	Hepatic Angiosarcoma May Have Fair Survival Nowadays. <i>Medicine (United States)</i> , 2015, 94, e816.	1.0	24
146	2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma. <i>Korean Journal of Radiology</i> , 2015, 16, 465.	3.4	168
147	The Korean guideline for hepatocellular carcinoma surveillance. <i>Journal of the Korean Medical Association</i> , 2015, 58, 385.	0.3	14
148	Current Role of Contrast-Enhanced Ultrasound in the Diagnosis of Hepatocellular Carcinoma. <i>Journal of Hepatology and Gastrointestinal Disorders</i> , 2015, 01, .	0.0	1
149	Foreword. <i>Digestive Diseases</i> , 2015, 33, 633-634.	1.9	0

#	ARTICLE	IF	CITATIONS
150	Serum Endocan as a Survival Predictor for Patients with Liver Cirrhosis. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 427-430.	1.9	14
151	Diagnosis of Hepatocellular Carcinoma Nodules in Patients With Chronic Liver Disease Using Contrast-enhanced Sonography. Journal of Ultrasound in Medicine, 2015, 34, 423-433.	1.7	14
152	Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. Hepatology, 2015, 61, 895-904.	7.3	105
153	Surgical and Locoregional Therapy of HCC: TACE. Liver Cancer, 2015, 4, 165-175.	7.7	154
154	Local tumour progression after ultrasound-guided microwave ablation of liver malignancies: risk factors analysis of 2529 tumours. European Radiology, 2015, 25, 1119-1126.	4.5	66
155	Elevated Alpha-Fetoprotein. Clinics in Liver Disease, 2015, 19, 309-323.	2.1	118
156	Helicobacter pylori Eradication to Eliminate Gastric Cancer. Gastroenterology Clinics of North America, 2015, 44, 639-648.	2.2	34
157	Factors Associated with Short-Term Local Recurrence of Liver Cancer after Percutaneous Ablation Using Irreversible Electroporation: A Prospective Single-Center Study. Journal of Vascular and Interventional Radiology, 2015, 26, 694-702.	0.5	60
158	Value of dynamic contrast enhanced MRI in predicting outcomes of HCC receiving radiotherapy. Hepatology International, 2015, 9, 155-156.	4.2	0
159	Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe. Liver Cancer, 2015, 4, 85-95.	7.7	83
160	2014 KLCSC-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut and Liver, 2015, 9, 267-317.	2.9	167
161	A Comparison of the Surgical Outcomes Among Patients With HBV-positive, HCV-positive, and Non-B Non-C Hepatocellular Carcinoma. Annals of Surgery, 2015, 261, 513-520.	4.2	130
162	Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review. American Journal of Roentgenology, 2015, 205, 764-773.	2.2	27
163	Evidence-based clinical practice guidelines for hepatocellular carcinoma: The Japanese Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatology Research, 2015, 45, .	3.4	339
164	Serum DHCR24 Auto-antibody as a new Biomarker for Progression of Hepatitis C. EBioMedicine, 2015, 2, 604-612.	6.1	14
165	Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis. Clinical Drug Investigation, 2015, 35, 751-759.	2.2	26
166	Complications Following Hepatectomy. Surgical Oncology Clinics of North America, 2015, 24, 73-96.	1.5	37
167	Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 8271.	3.3	33

#	ARTICLE	IF	CITATIONS
168	The serum level of NX-DCP-R, but not DCP, is not increased in alcoholic liver disease without hepatocellular carcinoma. <i>Cancer Biomarkers</i> , 2016, 16, 171-180.	1.7	1
169	Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis?: A multicenter study. <i>Hepatology Research</i> , 2016, 46, 521-528.	3.4	7
170	Surveillance for Hepatocellular Carcinoma. , 2016, , 339-354.		1
171	Hepatitis C and Hepatocellular Carcinoma. , 2016, , 261-273.		0
172	Usefulness of early vascular phase images from contrast-enhanced ultrasonography using Sonazoid for the diagnosis of hypovascular hepatocellular carcinoma. <i>Hepatology Research</i> , 2016, 46, 497-504.	3.4	9
173	Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan. <i>Liver Cancer</i> , 2016, 5, 190-197.	7.7	122
174	Imaging Diagnosis of Hepatocellular Carcinoma: Recent Advances of Contrast-Enhanced Ultrasonography with SonoVue®. <i>Liver Cancer</i> , 2016, 5, 55-66.	7.7	20
175	Evaluating the current surgical strategies for hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 341-357.	3.0	7
176	Surveillance rates for hepatocellular carcinoma among patients with cirrhosis, chronic hepatitis B, and chronic hepatitis C based on Japanese claims database. <i>Hepatology Research</i> , 2017, 47, 283-292.	3.4	8
177	Management and prognosis of hepatocellular carcinoma in the elderly: Results of an in-field multicenter cohort study. <i>Liver International</i> , 2017, 37, 1184-1192.	3.9	15
178	Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. <i>Journal of Gastroenterology</i> , 2017, 52, 1112-1121.	5.1	27
179	Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. <i>Medicine (United States)</i> , 2017, 96, e5811.	1.0	111
180	Should AFP (or Any Biomarkers) Be Used for HCC Surveillance?. <i>Current Hepatology Reports</i> , 2017, 16, 137-145.	0.9	26
181	Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2017, 77, 175-183.	1.2	16
182	New concepts in embolotherapy of HCC. <i>Medical Oncology</i> , 2017, 34, 58.	2.5	53
183	Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. <i>Liver Cancer</i> , 2017, 6, 325-336.	7.7	202
184	Serum levels of anti-SP9-associated antigen 9 antibody are elevated in patients with hepatocellular carcinoma. <i>Oncology Letters</i> , 2017, 14, 7608-7614.	1.8	5
185	Effect of ultrasonography surveillance in patients with liver cancer: a population-based longitudinal study. <i>BMJ Open</i> , 2017, 7, e015936.	1.9	2

#	ARTICLE	IF	CITATIONS
186	Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. Journal of Hepatology, 2017, 66, 347-354.	3.7	103
187	ICG Clearance Test and 99mTc-GSA SPECT/CT Fusion Images. Visceral Medicine, 2017, 33, 449-454.	1.3	18
188	Coefficient of variation on Gd-EOB MR imaging: Correlation with the presence of early-stage hepatocellular carcinoma in patients with chronic hepatitis B. European Journal of Radiology, 2018, 102, 95-101.	2.6	4
189	Hepatocellular carcinoma surveillance with ultrasound—cost-effectiveness, high-risk populations, uptake. British Journal of Radiology, 2018, 91, 20170436.	2.2	7
190	Impact of resection and ablation for single hypovascular hepatocellular carcinoma analysed with propensity score weighting. Liver International, 2018, 38, 484-493.	3.9	38
191	Muscle volume loss a prognostic factor for death in liver cirrhosis patients and special relationship to portal hypertension. Hepatology Research, 2018, 48, E354-E359.	3.4	14
192	Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ. Abdominal Radiology, 2018, 43, 3-12.	2.1	47
193	Impact of muscle volume and muscle function decline in patients undergoing surgical resection for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1271-1276.	2.8	21
194	Risk stratification using a novel liver functional reserve score of combination prothrombin time—international normalized ratio to albumin ratio and albumin in patients with hepatocellular carcinoma. Surgery, 2018, 164, 404-410.	1.9	24
195	Post-operative albumin-bilirubin grade predicts long-term outcomes among Child—Pugh grade A patients with hepatocellular carcinoma after curative resection. Hepatobiliary and Pancreatic Diseases International, 2018, 17, 502-509.	1.3	15
196	Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver Cancer, 2019, 8, 121-129.	7.7	159
197	Multimodal radiofrequency ablation versus laparoscopic hepatic resection for the treatment of primary hepatocellular carcinoma within Milan criteria in severely cirrhotic patients: long-term favorable outcomes over 10 years. Surgical Endoscopy and Other Interventional Techniques, 2019, 33, 46-51.	2.4	15
198	Pre-TACE kurtosis of ADCtotal derived from histogram analysis for diffusion-weighted imaging is the best independent predictor of prognosis in hepatocellular carcinoma. European Radiology, 2019, 29, 213-223.	4.5	22
199	Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th) Tokyo Guidelines. Journal of Hepatology, 2019, 70, 835-864.	3.4	899
200	Ultrasonography surveillance improves prognosis of patients with hepatocellular carcinoma. Molecular and Clinical Oncology, 2019, 11, 325-330.	1.0	0
201	Validation of a novel model for the early detection of hepatocellular carcinoma. Clinical Proteomics, 2019, 16, 2.	2.1	21
202	Combination of Resection and Ablative Treatment for Hepatocellular Carcinoma: Usefulness of Complementary Radiofrequency Ablation. Oncology, 2019, 96, 242-251.	1.9	8
203	Comparison of parallel and crossed placement of antennas in microwave ablation of 3–5 cm hepatocellular carcinoma. Abdominal Radiology, 2019, 44, 2293-2300.	2.1	3

#	ARTICLE	IF	CITATIONS
204	Assessment of the effect of the Aquamantys® system on local recurrence after hepatectomy for hepatocellular carcinoma through propensity score matching. Clinical and Translational Oncology, 2019, 21, 1634-1643.	2.4	3
205	The impact of age and ageing on hepatocarcinoma surgery: Short- and long-term outcomes in a multicentre propensity-matched cohort. Liver International, 2019, 39, 894-904.	3.9	15
207	Three-dimensional contrast-enhanced ultrasound fusion imaging predicts local tumor progression by evaluating ablative margin of radiofrequency ablation for hepatocellular carcinoma: a preliminary report. International Journal of Hyperthermia, 2019, 36, 55-64.	2.5	17
208	Impact of Advanced Age on Survival in Patients Undergoing Resection of Hepatocellular Carcinoma. Annals of Surgery, 2019, 269, 692-699.	4.2	53
209	Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort. Annals of Surgery, 2019, 270, 121-130.	4.2	48
210	Endoscopic hepatic resection and endoscopic radiofrequency ablation as initial treatments for hepatocellular carcinoma within the Milan criteria. Surgery Today, 2020, 50, 402-412.	1.5	8
211	Zinc deficiency as an independent prognostic factor for patients with early hepatocellular carcinoma due to hepatitis virus. Hepatology Research, 2020, 50, 92-100.	3.4	13
212	Liver Resection for Multiple Hepatocellular Carcinomas. Annals of Surgery, 2020, 272, 145-154.	4.2	61
213	Traditional Chinese medicine as supportive care for the management of liver cancer: Past, present, and future. Genes and Diseases, 2020, 7, 370-379.	3.4	76
214	Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with small hepatocellular carcinoma treated by radiofrequency ablation. Cancer Imaging, 2020, 20, 74.	2.8	2
215	Clinical outcomes of direct-acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment. Hepatology Research, 2020, 50, 1118-1127.	3.4	15
216	Avoidance of bile duct injury during laparoscopic liver cyst fenestration using indocyanine green: A case report. Clinical Case Reports (discontinued), 2020, 8, 1419-1424.	0.5	6
217	Impact of systematic segmentectomy for small hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2020, 27, 331-341.	2.6	16
218	A Novel Noninvasive Method for Predicting Liver Fibrosis by Quantifying the Estrangement of Indocyanine Green Retention Rate and Tc-99m-diethylenetriamine-penta-acetic Acid-galactosyl Human Serum Albumin Scintigraphy. In Vivo, 2020, 34, 1187-1193.	1.3	2
219	NAFLD and NASH. , 2020, , .		1
220	Data driven decision-making for older patients with hepatocellular carcinoma. European Journal of Surgical Oncology, 2021, 47, 576-582.	1.0	5
221	Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. Journal of Gastroenterology, 2021, 56, 90-100.	5.1	25
222	Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer, 2021, 10, 181-223.	7.7	307

#	ARTICLE	IF	CITATIONS
223	Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: Report of a Japanese nationwide survey. <i>Hepatology Research</i> , 2021, 51, 890-901.	3.4	5
224	Transmediastinal, intrapericardial inferior vena cava approach based on anatomical landmarks for hepatectomy using total hepatic vascular exclusion. <i>Langenbeck's Archives of Surgery</i> , 2021, , 1.	1.9	0
225	Baseline Alpha-Fetoprotein, Alpha-Fetoprotein-L3, and Des-Gamma-Carboxy Prothrombin Biomarker Status in Bridge to Liver Transplant Outcomes for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4765.	3.7	4
226	Anatomic Resection for Hepatocellular Carcinoma: Prognostic Impact Assessed from Recurrence Treatment. <i>Annals of Surgical Oncology</i> , 2022, 29, 913-921.	1.5	15
230	Hepatitis C and Hepatocellular Carcinoma. , 2009, , 259-281.		4
231	Screening Program in High-Risk Populations. , 2011, , 55-68.		2
232	Surgical Resection for Small Hepatocellular Carcinoma in Cirrhosis: The Eastern Experience. <i>Recent Results in Cancer Research</i> , 2013, 190, 69-84.	1.8	3
233	Quality Assessment of Clinical Practice Guidelines on the Treatment of Hepatocellular Carcinoma or Metastatic Liver Cancer. <i>PLoS ONE</i> , 2014, 9, e103939.	2.5	17
234	BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. <i>Arquivos De Gastroenterologia</i> , 2020, 57, 1-20.	0.8	22
235	Long-term Favorable Outcomes of Radiofrequency Ablation for Hepatocellular Carcinoma as an Initial Treatment: A Single-center Experience Over a 10-Year Period. <i>Anticancer Research</i> , 2018, 38, 1047-1052.	1.1	9
236	Preventive Effects of Vitamin C on Diethylnitrosamine-induced Hepatotoxicity in Smp30 Knockout Mice. <i>In Vivo</i> , 2018, 32, 93-99.	1.3	8
237	A Web-Based Data-Querying Tool Based on Ontology-Driven Methodology and Flowchart-Based Model. <i>JMIR Medical Informatics</i> , 2013, 1, e2.	2.6	4
238	Diagnostic and Prognostic Value of Talin-1 and Midkine as Tumor Markers in Hepatocellular Carcinoma in Egyptian Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 1503-1508.	1.2	12
239	Clinical biomarkers in hepatocellular carcinoma HCC. <i>Frontiers in Bioscience - Scholar</i> , 2010, S2, 571-577.	2.1	13
240	HCC Screening and Surveillance. , 2009, , 26-35.		1
242	Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease. <i>World Journal of Gastroenterology</i> , 2008, 14, 3452.	3.3	45
243	Local recurrence of hepatocellular carcinoma after radiofrequency ablation. <i>World Journal of Gastroenterology</i> , 2010, 16, 5135.	3.3	4
244	Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography. <i>World Journal of Gastroenterology</i> , 2012, 18, 1385.	3.3	10

#	ARTICLE	IF	CITATIONS
245	Alcohol, postprandial plasma glucose, and prognosis of hepatocellular carcinoma. World Journal of Gastroenterology, 2013, 19, 78.	3.3	12
246	Clinical outcome of small hepatocellular carcinoma after different treatments: A meta-analysis. World Journal of Gastroenterology, 2014, 20, 10174.	3.3	47
247	Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit. World Journal of Gastroenterology, 2014, 20, 11595.	3.3	42
248	Clinical outcome of medium-sized hepatocellular carcinoma treated with microwave ablation. World Journal of Gastroenterology, 2015, 21, 2997.	3.3	46
249	Current status of hepatocellular carcinoma in Japan. Chinese Clinical Oncology, 2013, 2, 40.	1.2	20
250	Perspectives on using des-Î³-carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in China. Hepatobiliary Surgery and Nutrition, 2013, 2, 227-31.	1.5	20
251	Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma. World Journal of Hepatology, 2014, 6, 836.	2.0	18
252	Management of hepatocellular carcinoma in the elderly. World Journal of Hepatology, 2015, 7, 1521.	2.0	31
253	Current Limitations and Potential Breakthroughs for the Early Diagnosis of Hepatocellular Carcinoma. Gut and Liver, 2011, 5, 15-21.	2.9	33
254	Serum Talin-1 is a Potential Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Egyptian Patients. Asian Pacific Journal of Cancer Prevention, 2013, 14, 3819-3823.	1.2	30
255	Plasma Nuclear Factor Kappa B and Serum Peroxiredoxin 3 in Early Diagnosis of Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2015, 16, 1657-1663.	1.2	14
256	A study of hepatocellular carcinoma patients surviving for 10 years-Comparison of hepatectomy and percutaneous ablation therapy-. Journal of Microwave Surgery, 2009, 27, 65-70.	0.3	1
257	Evidence-Based Guidelines for Treatment of Hepatocellular Carcinoma in Japan. , 2011, , 89-97.		0
258	Investigation of different methods, particularly percutaneous ablation therapy, for treating non-B, non-C hepatocellular carcinoma. Journal of Microwave Surgery, 2011, 29, 99-104.	0.3	1
260	Use of ultrasound as the initial screening exam for hepatocellular carcinoma in high risk populations. Open Journal of Gastroenterology, 2013, 03, 148-154.	0.1	1
261	Comparison of the Outcomes of Hepatocellular Carcinoma Patients Following Local Ablation Therapy and Hepatectomy. Journal of Microwave Surgery, 2013, 31, 33-38.	0.3	0
262	Trans-arterial Chemo-Embolization in Treating Elderly Patients with Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2015, 16, 7201-7204.	1.2	0
263	Clinical significance and expression of serum Golgi protein 73 in primary hepatocellular carcinoma. Journal of Cancer Research and Therapeutics, 2018, 14, 1239-1244.	0.9	17

#	ARTICLE	IF	CITATIONS
264	Preoperative Controlling Nutritional Status plus Tumor Burden Score for the Assessment of Prognosis after Curative Liver Resection for Hepatocellular Carcinoma. Medical Principles and Practice, 2021, 30, 131-137.	2.4	8
265	HCC in Patients with NAFLD/NASH. , 2020, , 191-203.		0
267	Accomplishments in 2007 in the management of hepatobiliary cancers. Gastrointestinal Cancer Research: GCR, 2008, 2, S25-31.	0.7	5
269	Preventive Effect of Geraniol on Diethylnitrosamine-Induced Hepatocarcinogenesis in Rats. Yonago Acta Medica, 2016, 59, 37-43.	0.7	9
270	Guidelines for the management of hepatocellular carcinoma: still in need of standardization. Chinese Clinical Oncology, 2012, 1, 15.	1.2	0
271	Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer. Cancers, 2022, 14, 2295.	3.7	3
272	Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis. Journal of Clinical Medicine, 2022, 11, 5075.	2.4	8
274	Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review. International Journal of Molecular Sciences, 2023, 24, 4286.	4.1	11
275	Screening of liver cancer with abbreviated MRI. Hepatology, 2023, 78, 670-686.	7.3	5
276	Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment Modality. Liver Cancer, 2023, 12, 565-575.	7.7	1
277	Evaluating the Effect of Artificial Liver Support on Acute-on-Chronic Liver Failure Using the Quantitative Difference Algorithm: Retrospective Study. JMIR Formative Research, 0, 7, e45395.	1.4	0
278	Novel Blood-Based Biomarkers for HCC. Current Hepatology Reports, 2024, 23, 174-184.	0.9	0